Prognostic value of Hedgehog signal component expressions in hepatoblastoma patients

European Journal of Medical Research

Volumn 15, Issue 11, 2010, Pages 468-474

  Li, Ying Cun ^a   Deng, Yu Hua ^a   Guo, Zhen Hua ^a   Zhang, Ming Alan ^a   Zhu, Jin ^a   Pu, Chon Lun ^a   Xiang, Chun Ping ^a   Guo, Chun Bao ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Hedgehog (Hh); Hepatoblastoma; Indicator; Prognosis

Indexed keywords

MOLECULAR MARKER; SMOOTHENED PROTEIN; SONIC HEDGEHOG PROTEIN; TRANSCRIPTION FACTOR GLI1;

ARTICLE; CANCER GRADING; CANCER PATIENT; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CHILD; CHOLESTASIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEPATOBLASTOMA; HISTOLOGY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFANT; KAPLAN MEIER METHOD; MALE; PROGNOSIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TISSUE SECTION;

EID: 78650188821     PISSN: 09492321     EISSN: None     Source Type: Journal    
DOI: 10.1186/2047-783x-15-11-468     Document Type: Article

References (23)

1. Hiyama E, Yamaoka H, Matsunaga T, Hayashi Y, Ando H, Suita S, Horie H, Kaneko M, Sasaki F, Hashizume K, Nakagawara A, Ohnuma N, Yokoyama T. High expression of telomerase is an independent prognostic indicator of poor outcome in hepatoblastoma. Br J Cancer. 2004; 91(5):972-979.
2. Wang LL, Filippi RZ, Zurakowski D, Archibald T, Vargas SO, Voss SD, Shamberger RC, Davies K, Kozakewich H, Perez-Atayde AR. Effects of neoadjuvant chemotherapy on hepatoblastoma: a morphologic and immunohistochemical study. Am J Surg Pathol. 2010;34(3):287-299.
3. Hou JY, Liu HC, Yeh TC, Chen SH, Wang LY, Sheu JC, Liang DC. Long-term treatment results of hepatoblastoma at a single institution in Taiwan. J Pediatr Hematol Oncol. 2009;31(10):718-722.
4. Sakamoto LH, DE Camargo B, Cajaiba M, Soares FA, Vettore AL. MT1G Hypermethylation: A Potential Prognostic Marker for Hepatoblastoma. Pediatr Res. 2010; 67(4):387-393.
5. Oue T, Yoneda A, Uehara S, Yamanaka H, Fukuzawa M. Increased expression of the hedgehog signaling pathway in pediatric solid malignancies. J Pediatr Surg. 2010;45(2): 387-392.
6. von Schweinitz D, Kraus JA, Albrecht S, Koch A, Fuchs J, Pietsch T. Prognostic impact of molecular genetic alterations in hepatoblastoma. Med Pediatr Oncol. 2002;38(2): 104-108. (Pubitemid 34113439)
7. Weber RG, Pietsch T, von Schweinitz D, Lichter P. Characterization of genomic alterations in hepatoblastomas. A role for gains on chromosomes 8q and 20 as predictors of poor outcome. Am J Pathol. 2000;157(2):571-578. (Pubitemid 30627562)
8. Kameda C, Tanaka H, Yamasaki A, Nakamura M, Koga K, Sato N, Kubo M, Kuroki S, Tanaka M, Katano M. The Hedgehog pathway is a possible therapeutic target for patients with estrogen receptor-negative breast cancer. Anticancer Res. 2009;29(3):871-879.
9. Liao X, Siu MK, Au CW, Wong ES, Chan HY, Ip PP, Ngan HY, Cheung AN. Aberrant activation of hedgehog signaling pathway in ovarian cancers: effect on prognosis, cell invasion and differentiation. Carcinogenesis. 2009; 30(1):131-140.
10. Yoshikawa R, Nakano Y, Tao L, Koishi K, Matsumoto T, Sasako M, Tsujimura T, Hashimoto-Tamaoki T, Fujiwara Y. Hedgehog signal activation in oesophageal cancer patients undergoing neoadjuvant chemoradiotherapy. Br J Cancer. 2008;98(10):1670-1674.
11. Lauth M, Toftgård R. The Hedgehog pathway as a drug target in cancer therapy. Curr Opin Investig Drugs. 2007;8(6):457-461. (Pubitemid 46868067)
12. Haas JE, Muczynski KA, Krailo M, Ablin A, Land V, Vietti TJ, Hammond GD. Histopathology and prognosis in childhood hepatoblastoma and hepatocarcinoma. Cancer. 1989;64(5):1082-1095.
13. Zhang D, Qiu L, Jin X, Guo Z, Guo C. Nuclear factor-kappaB inhibition by parthenolide potentiates the efficacy of Taxol in non-small cell lung cancer in vitro and in vivo. Mol Cancer Res. 2009;7(7):1139-1149.
14. Yagui-Beltrán A, He B, Raz D, Kim J, Jablons DM. Novel therapies targeting signaling pathways in lung cancer. Thorac Surg Clin. 2006;16(4):379-396. (Pubitemid 44828811)
15. Mori Y, Okumura T, Tsunoda S, Sakai Y, Shimada Y. Gli-1 expression is associated with lymph node metastasis and tumor progression in esophageal squamous cell carcinoma. Oncology. 2006;70(5):378-389. (Pubitemid 46066131)
16. Chen X, Horiuchi A, Kikuchi N, Osada R, Yoshida J, Shiozawa T, Konishi I. Hedgehog signal pathway is activated in ovarian carcinomas, correlating with cell proliferation: it's inhibition leads to growth suppression and apoptosis. Cancer Sci. 2007;98(1):68-76.
17. Ferretti E, Di Marcotullio L, Gessi M, Mattei T, Greco A, Po A, De Smaele E, Giangaspero F, Riccardi R, Di Rocco C, Pazzaglia S, Maroder M, Alimandi M, Screpanti I, Gulino A. Alternative splicing of the ErbB-4 cytoplasmic domain and its regulation by hedgehog signaling identify distinct medulloblastoma subsets. Oncogene. 2006;25(55): 7267-7273.
18. Nolan-Stevaux O, Lau J, Truitt ML, Chu GC, Hebrok M, Fernández- Zapico ME, Hanahan D. GLI1 is regulated through Smoothened-independent mechanisms in neoplastic pancreatic ducts and mediates PDAC cell survival and transformation. Genes Dev. 2009;23(1):24-36.
19. Yoshizaki A, Nakayama T, Naito S, Wen CY, Sekine I. Expressions of sonic hedgehog, patched, smoothened and Gli-1 in human intestinal stromal tumors and their correlation with prognosis. World J Gastroenterol. 2006; 12(35):5687-5691. (Pubitemid 44594045)
20. Kim KH, Kim JM, Choi YL, Shin YK, Lee HC, Seong IO, Kim BK, Chae SW, Chung YS, Kim SH. Expression of sonic hedgehog signaling molecules in normal, hyperplastic and carcinomatous endometrium. Pathol Int. 2009; 59(5):279-287.
21. Hochman E, Castiel A, Jacob-Hirsch J, Amariglio N, Izraeli S. Molecular pathways regulating pro-migratory effects of Hedgehog signaling. J Biol Chem. 2006;281(45): 33860-33870.
22. Davidson B, Goldberg I, Gotlieb WH, Kopolovic J, Risberg B, Ben-Baruch G, Reich R. Coordinated expression of integrin subunits, matrix metalloproteinases (MMP), angiogenic genes and Ets transcription factors in advanced-stage ovarian carcinoma: a possible activation pathway? Cancer Metastasis Rev. 2003;22(1):103-115.
23. Sodek KL, Ringuette MJ, Brown TJ. MT1-MMP is the critical determinant of matrix degradation and invasion by ovarian cancer cells. Br J Cancer. 2007;97(3):358-367.